Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma.
about
Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease.Successful treatment with anti-programmed-death-1 antibody in a relapsed natural killer/T-cell lymphoma patient with multi-line resistance: a case report.Comparison of Native Escherichia Coli L-Asparaginase Versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone (IMEP), in Extranodal NK/T Cell Lymphoma, Nasal Type (NTCL).PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity
P2860
Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 April 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy of combined gemcitabi ...... extranodal NK/T-cell lymphoma.
@en
Efficacy of combined gemcitabi ...... extranodal NK/T-cell lymphoma.
@nl
type
label
Efficacy of combined gemcitabi ...... extranodal NK/T-cell lymphoma.
@en
Efficacy of combined gemcitabi ...... extranodal NK/T-cell lymphoma.
@nl
prefLabel
Efficacy of combined gemcitabi ...... extranodal NK/T-cell lymphoma.
@en
Efficacy of combined gemcitabi ...... extranodal NK/T-cell lymphoma.
@nl
P2093
P2860
P356
P1433
P1476
Efficacy of combined gemcitabi ...... extranodal NK/T-cell lymphoma.
@en
P2093
Cheng-Cheng Liu
Hui-Qiang Huang
Jing-Hua Wang
Liang Wang
Tong-Yu Lin
Wen-Qi Jiang
Zhong-Jun Xia
P2860
P304
29092-29101
P356
10.18632/ONCOTARGET.8647
P407
P577
2016-04-08T00:00:00Z